Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 10/20 | 0.57 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.57 |
| ▸ | PRKG1 | Q13976 | 4/20 | 0.57 |
| ▸ | RPS6KA5 | O75582 | 3/20 | 0.57 |
| ▸ | CDK1 | P06493 | 3/20 | 0.57 |
| ▸ | PRKACA | P17612 | 3/20 | 0.57 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.57 |
| ▸ | CDK2 | P24941 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.57 |
| ▸ | GSK3A | P49840 | 3/20 | 0.57 |
| ▸ | GSK3B | P49841 | 3/20 | 0.57 |
| ▸ | PRKX | P51817 | 3/20 | 0.57 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.57 |
| ▸ | PRKG2 | Q13237 | 3/20 | 0.57 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.57 |
| ▸ | CDC42BPA | Q5VT25 | 3/20 | 0.57 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.57 |
| ▸ | SGK2 | Q9HBY8 | 3/20 | 0.57 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.57 |
| ▸ | AKT1 | P31749 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5224427 | 1.00 | ROCK2 (0.57) | ROCK2ROCK1PRKG1RPS6KA5CDK1 | |
| SCHEMBL12191087 | 0.85 | ROCK2 (0.57) | ROCK2ROCK1PRKG1RPS6KA5CDK1 | |
| SCHEMBL12191029 | 0.85 | ROCK2 (0.57) | ROCK2ROCK1PRKG1RPS6KA5CDK1 | |
| SCHEMBL5888532 | 0.85 | ALDH1A1 (0.50) | ROCK2ROCK1PRKG1RPS6KA5CDK1 | |
| SCHEMBL5888537 | 0.85 | ALDH1A1 (0.50) | ROCK2ROCK1PRKG1RPS6KA5CDK1 | |
| SCHEMBL14880128 | 0.83 | ROCK2 (0.63) | ROCK2ROCK1PRKG1RPS6KA5CDK1 | |
| SCHEMBL10822708 | 0.83 | ROCK2 (0.63) | ROCK2ROCK1PRKG1RPS6KA5CDK1 | |
| SCHEMBL5888653 | 0.81 | CTSL (0.52) | CTSLCTSSKMOALDH1A1CTSK | |
| SCHEMBL5888488 | 0.81 | CTSL (0.49) | CTSLCTSSKMOALDH1A1CYP3A4 | |
| SCHEMBL5888650 | 0.81 | CTSL (0.52) | CTSLCTSSKMOALDH1A1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581516-A4 | 3-HETEROCYCLIC BENZYLAMIDE DERIVATIVES AS POTASSIUM CHANNEL OPENERS | BRISTOL MYERS SQUIBB CO (US) | 2007-10-17 | — | — | EP | claimed |
| US-7135472-B2 | 3-Heterocyclic benzylamide derivatives as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-14 | — | — | US | claimed |
| EP-1581516-A2 | 3-HETEROCYCLIC BENZYLAMIDE DERIVATIVES AS POTASSIUM CHANNEL OPENERS | Bristol-Myers Squibb Company (US) | 2005-10-05 | — | — | EP | claimed |
| WO-2004047744-A2 | 3-HETEROCYCLIC BENZYLAMIDE DERIVATIVES AS POTASSIUM CHANNEL OPENERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-10 | — | — | WO | claimed |
| US-20040106621-A1 | 3-Heterocyclic benzylamide derivatives as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-03 | — | — | US | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-7135472-B2 | 3-Heterocyclic benzylamide derivatives as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-14 | — | — | US | disclosed |
| US-20040106621-A1 | 3-Heterocyclic benzylamide derivatives as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106621-A1 | 3-Heterocyclic benzylamide derivatives as potassium channel openers | KCNQ3, KCNQ5, KCNQ2 | ROCK2 3051/4885ROCK1 2861/4885PRKG1 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.